Harmon Patrick, MD
Family Medicine · Winnsboro, SCNPI 1174546287
Payments from drug & device makers
Across 362 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$765
- AstraZeneca$599
- Dexcom, Inc.$404
- Amarin Pharma, Inc.$401
- AbbVie$397
- Lilly USA, LLC$360
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $765 |
| AstraZeneca | 39 | $599 |
| Dexcom, Inc. | 13 | $404 |
| Amarin Pharma, Inc. | 27 | $401 |
| AbbVie(2 entities) | 43 | $397 |
| Lilly USA, LLC | 24 | $360 |
| Amgen | 21 | $342 |
| Pfizer | 13 | $219 |
| Johnson & Johnson | 14 | $218 |
| Bayer | 11 | $171 |
| GSK | 10 | $141 |
| Merck | 9 | $116 |
| Boehringer Ingelheim | 7 | $115 |
| Eisai Inc. | 6 | $97 |
| Kowa Pharmaceuticals America, Inc. | 7 | $94 |
| Novartis | 5 | $86 |
| Esperion Therapeutics, Inc. | 3 | $79 |
| Lundbeck LLC | 3 | $74 |
| Grifols USA, LLC | 3 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $63 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Corcept Therapeutics | 3 | $49 |
| Exact Sciences | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Vivus LLC | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Ironwood Pharmaceuticals, Inc | 3 | $38 |
| Astellas Pharma US Inc | 2 | $33 |
| Edwards Lifesciences | 2 | $33 |
| Strongbridge US Inc. | 2 | $29 |
| Optinose US, Inc. | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 2 | $27 |
| Abbott | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Stryker | 1 | $16 |
| Medtronic | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
How this compares
$5,458 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 126 | $116,569 |
| JardianceEmpagliflozin | 123 | $103,384 |
| OzempicSemaglutide | 94 | $102,617 |
| EliquisApixaban | 120 | $80,704 |
| TrulicityDulaglutide | 27 | $44,849 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $29,478 |
| LinzessLinaclotide | 28 | $28,237 |
| RybelsusSemaglutide | 24 | $27,655 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $20,756 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $20,360 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $19,922 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $19,849 |
| XareltoRivaroxaban | 30 | $18,819 |
| MyrbetriqMirabegron | 19 | $18,227 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 79 | $17,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Qtern | $599 | $142,926166 claims |
| Novo NordiskOzempic, Rybelsus | $765 | $130,272118 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $115 | $121,484156 claims |
| PfizerEliquis, Dilantin | $219 | $83,693137 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta, Anoro Ellipta | $141 | $78,154205 claims |
| Lilly USA, LLCTrulicity | $360 | $44,84927 claims |
| AbbVieLinzess, Namzaric | $397 | $42,03448 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $54 | $19,84919 claims |
| Johnson & JohnsonXarelto | $218 | $18,81930 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $18,22719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Winnsboro
- Stephen BruntonWinnsboro$1.3M
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.